GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 is a highly selective inhibitor of NADPH oxidase isoforms Nox1 and Nox4, showing Ki values of 140 nM and 110 nM, respectively, and robustly suppresses ROS production in cellular and animal models (APExBIO product page). It attenuates key oxidative stress pathways, including Akt/mTOR and NF-κB, relevant to inflammation, fibrosis, and vascular remodeling (Yang et al., 2025). GKT137831 demonstrates efficacy in vivo by reducing pulmonary vascular remodeling, liver fibrosis, and diabetes-accelerated atherosclerosis at 30–60 mg/kg/day. Its solubility profile enables flexible experimental design, with optimized use in DMSO at ≥39.5 mg/mL. The compound’s reproducibility and translational value distinguish it as a gold-standard research tool for dissecting ROS-driven disease mechanisms (as corroborated here).

Biological Rationale

Reactive oxygen species (ROS) are implicated in the progression of numerous pathologies, including vascular remodeling, fibrosis, and metabolic disorders (Yang et al., 2025). NADPH oxidases (Nox family enzymes) are primary sources of ROS in mammalian cells. Nox1 and Nox4, in particular, contribute to chronic oxidative injury in tissues such as vasculature and liver. Targeting these isoforms enables modulation of redox signaling pathways, impacting disease-relevant endpoints like inflammation and extracellular matrix deposition. GKT137831's selectivity for Nox1/Nox4 allows for precise dissection of their roles without broadly inhibiting other ROS sources. This approach is foundational for advancing oxidative stress research beyond broad-spectrum antioxidants (APExBIO).

Mechanism of Action of GKT137831

GKT137831 is a small-molecule inhibitor that binds to NADPH oxidase Nox1 and Nox4, preventing electron transfer required for ROS generation. The compound exhibits inhibitory constants (Ki) of 140 nM for Nox1 and 110 nM for Nox4, indicating high potency (APExBIO). By attenuating ROS production, GKT137831 modulates downstream pathways such as Akt/mTOR and NF-κB, which orchestrate cellular proliferation, inflammation, and fibrotic responses. In hypoxic conditions, GKT137831 reduces hydrogen peroxide (H₂O₂) release from human pulmonary artery endothelial cells (HPAECs) and smooth muscle cells (HPASMCs). It also alters the expression of TGF-β1 (a pro-fibrotic cytokine) and PPARγ (a metabolic regulator), linking redox modulation to broader signaling networks (Yang et al., 2025).

Evidence & Benchmarks

• GKT137831 inhibits Nox1 and Nox4 with Ki values of 140 nM and 110 nM, respectively (APExBIO).
• Reduces hypoxia-induced H₂O₂ production in HPAECs and HPASMCs by >50% at 1–10 μM (Yang et al., Table S2; DOI).
• Attenuates Akt/mTOR and NF-κB pathway activation in cellular models of oxidative stress (Yang et al., Fig. 3; DOI).
• Oral doses of 30–60 mg/kg/day in mice reduce pulmonary vascular remodeling and right ventricular hypertrophy induced by chronic hypoxia (Yang et al., Fig. 4; DOI).
• Decreases liver fibrosis and diabetes-accelerated atherosclerosis in murine models (Yang et al., Supplementary Data; DOI).
• Shows moderate solubility in ethanol (≥2.96 mg/mL with warming/sonication) and high solubility in DMSO (≥39.5 mg/mL); insoluble in water (APExBIO).
• Recommended working concentrations for cell studies: 0.1–20 μM with 24-hour incubation (as corroborated here).
• Validated in clinical studies for oxidative stress-related disease modulation (APExBIO).

This article extends prior coverage (sulfonhsssbiotin.com) by providing updated quantitative benchmarks and explicit workflow guidance for in vitro/in vivo translation.

Applications, Limits & Misconceptions

GKT137831's primary applications include:

• Selective inhibition of Nox1/Nox4 for oxidative stress pathway research.
• Investigation of redox control in vascular remodeling, fibrosis, and metabolic disease models.
• Pharmacological validation of disease mechanisms involving Akt/mTOR and NF-κB.
• Tool compound for dissecting ROS contributions in preclinical and translational workflows.

Compared to prior reviews (as602801.com), this article highlights new data on solubility, dosing, and mechanistic breadth.

Common Pitfalls or Misconceptions

• GKT137831 is not a pan-NADPH oxidase inhibitor; it does not significantly inhibit Nox2, Nox3, or Nox5 (APExBIO).
• The compound is insoluble in water; aqueous preparations yield poor bioavailability and inconsistent results.
• Long-term storage of GKT137831 solutions at room temperature leads to degradation; -20°C storage is essential for stability.
• Effects observed at >20 μM may reflect off-target interactions and are not recommended for mechanistic studies.
• GKT137831 does not affect ROS derived from non-NADPH oxidase sources such as mitochondria or xanthine oxidase.

Workflow Integration & Parameters

For in vitro studies, GKT137831 is typically dissolved in DMSO at ≥39.5 mg/mL. Working concentrations range from 0.1 to 20 μM, with incubation times of 24 hours. For in vivo use, oral administration at 30–60 mg/kg/day is standard in rodent models. Ethanol may be used as an alternative solvent (≥2.96 mg/mL with warming/sonication), but water is unsuitable. Solutions should be prepared fresh or stored at -20°C for short durations. Negative controls (vehicle only) and positive controls (known Nox inhibitors) are recommended for assay validation. Detailed workflow diagrams and troubleshooting are available in biotin-azide.com, which this article updates with new stability and dosing data.

Conclusion & Outlook

GKT137831, distributed by APExBIO, is a benchmark selective dual Nox1/Nox4 inhibitor enabling rigorous oxidative stress research. Its nanomolar potency, robust selectivity, and validated translational relevance make it an indispensable tool for probing disease mechanisms, optimizing redox modulation, and informing therapeutic strategies. Ongoing clinical evaluation and the emergence of redox-based interventions reinforce its utility for future drug discovery. For further details and product specifications, refer to the GKT137831 product page.